{"id":951262,"date":"2026-04-14T09:53:41","date_gmt":"2026-04-14T13:53:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/"},"modified":"2026-04-14T09:53:41","modified_gmt":"2026-04-14T13:53:41","slug":"immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/","title":{"rendered":"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C."},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, April  14, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5SNiVglD38ltZ5LsZdMrfH4HxrGe0toGO6XKO-xFOUbfoD8yWIvx-Xb77XoJSzVuAIyL_tf1FvJsu9HOYPkcS3p3gcz5Bav3d9Yg4L9zvOU=\" rel=\"nofollow\" target=\"_blank\"><strong>Lowey Dannenberg P.C.<\/strong><\/a>, a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ: IBRX) (\u201cImmunityBio\u201d or the \u201cCompany\u201d) for potential violations of the federal securities laws.<\/p>\n<p align=\"justify\">On March 26, 2026, a complaint was filed against the Company and one of its current officer, alleging that throughout the Class Period, Defendants misrepresented and failed to disclose that: (1) Defendant Soon-Shion materially overstated Anktiva\u2019s capabilities; and (2) as a result, Defendants\u2019 statements about ImmunityBio\u2019s business, operations, and prospects were materially false and misleading and\/or lacked a reasonable basis at all relevant times.<\/p>\n<p align=\"justify\">\u201cOur investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,\u201d said attorney Andrea Farah, Lowey Dannenberg, P.C. partner and head of the firm\u2019s securities practice.<\/p>\n<p align=\"justify\">If you suffered a loss of more than $50,000 in ImmunityBio Inc. securities, and wish to participate, or learn more about your eligibility, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZJMTFgBwsfD2yLG72jsBOHcfvsfHzG6n-fVKUzM5OMtZcjVn3yxXrjTtoHSqYrm-AWWanoYjQgbz91ulZvbtgiUtZf_5KvrpvA4W_GJjUezgU-toNxv0Ki1L3fL80Xzl\" rel=\"nofollow\" target=\"_blank\"><strong>click here<\/strong><\/a>, or contact our attorneys Andrea Farah (afarah@lowey.com) at (914)733-7256 or Vincent R. Cappucci Jr. (vcappucci@lowey.com) at (914)733-7278.<\/p>\n<p align=\"justify\">\n        <strong>About Lowey Dannenberg<\/strong>\n      <\/p>\n<p align=\"justify\">Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.<\/p>\n<p>\n        <strong>Contact<\/strong>\n      <\/p>\n<p>Lowey Dannenberg P.C.<br \/>44 South Broadway, Suite 1100<br \/>White Plains, NY 10601<br \/>Tel: (914) 733-7256<br \/>Email:\u00a0 investigations@lowey.com<\/p>\n<p>\n        <strong>SOURCE:<\/strong>\u00a0Lowey Dannenberg<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjIzYWU0MjQtMDU4YS00N2VlLWEwNTQtNDk3ZWYzMDg0OTQ5LTEyMDYwODctMjAyNi0wNC0xNC1lbg==\/tiny\/Lowey-Dannenberg-P-C-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ: IBRX) (\u201cImmunityBio\u201d or the \u201cCompany\u201d) for potential violations of the federal securities laws. On March 26, 2026, a complaint was filed against the Company and one of its current officer, alleging that throughout the Class Period, Defendants misrepresented and failed to disclose that: (1) Defendant Soon-Shion materially overstated Anktiva\u2019s capabilities; and (2) as a result, Defendants\u2019 statements about ImmunityBio\u2019s business, operations, and prospects were materially false and misleading and\/or lacked a reasonable basis at all relevant times. \u201cOur investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,\u201d said attorney &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-951262","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ: IBRX) (\u201cImmunityBio\u201d or the \u201cCompany\u201d) for potential violations of the federal securities laws. On March 26, 2026, a complaint was filed against the Company and one of its current officer, alleging that throughout the Class Period, Defendants misrepresented and failed to disclose that: (1) Defendant Soon-Shion materially overstated Anktiva\u2019s capabilities; and (2) as a result, Defendants\u2019 statements about ImmunityBio\u2019s business, operations, and prospects were materially false and misleading and\/or lacked a reasonable basis at all relevant times. \u201cOur investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,\u201d said attorney &hellip; Continue reading &quot;ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T13:53:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C.\",\"datePublished\":\"2026-04-14T13:53:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/\"},\"wordCount\":265,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/\",\"name\":\"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ=\",\"datePublished\":\"2026-04-14T13:53:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/","og_locale":"en_US","og_type":"article","og_title":"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C. - Market Newsdesk","og_description":"NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) &#8212; Lowey Dannenberg P.C., a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ: IBRX) (\u201cImmunityBio\u201d or the \u201cCompany\u201d) for potential violations of the federal securities laws. On March 26, 2026, a complaint was filed against the Company and one of its current officer, alleging that throughout the Class Period, Defendants misrepresented and failed to disclose that: (1) Defendant Soon-Shion materially overstated Anktiva\u2019s capabilities; and (2) as a result, Defendants\u2019 statements about ImmunityBio\u2019s business, operations, and prospects were materially false and misleading and\/or lacked a reasonable basis at all relevant times. \u201cOur investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,\u201d said attorney &hellip; Continue reading \"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-14T13:53:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C.","datePublished":"2026-04-14T13:53:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/"},"wordCount":265,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/","name":"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ=","datePublished":"2026-04-14T13:53:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4OTQ2NSM3NTM0Njg1IzIxOTQ1MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunitybio-inc-nasdaq-ibrx-investigated-for-potential-federal-securities-laws-violations-lowey-dannenberg-p-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations \u2013 Lowey Dannenberg, P.C."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/951262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=951262"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/951262\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=951262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=951262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=951262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}